Citius Oncology, a subsidiary of Citius Pharmaceuticals, has signed an exclusive distribution agreement with Uniphar to access LYMPHIR™ (denileukin diftitox-cxdl) outside the United States.[1][2] Uniphar will be the exclusive distribution partner in designated Western and Eastern European countries through country managed access programs where permitted by local law.[1][2] Uniphar will manage market access and distribution activities in these selected territories.[1][2] Citius Oncology will deliver the finished product and provide ongoing support under the contract.[1][2] LYMPHIR is not approved for commercial use outside the US and will be provided exclusively through controlled access programs, which are not marketing approvals or commercial launches.[1][2] This contract is Citius Oncology's third international distribution agreement, following previous partnerships in Southern Europe, the Balkans, Turkey and the Middle East.[1][2] The agreement supports a strategy of global access to medicine for patients with limited treatment options.[1]